In order to realize the first Phase II clinical trial using the monoclonal antibody hu3S193, RECEPTA biopharma structured partnerships with various hospital Centers of Excellence: Sírio Libanes Hospital (SP), Clinical Hospital of the University of Sao Paulo (HC-SP), Oswaldo Cruz German Hospital (SP), The Brazilian Institute for Cancer Control (IBCC, SP), Baleia Hospital (BH), Clinical Hospital of the Federal University of Minas Gerais and the National Cancer Institute (INCA, RJ). In addition to having documented experience in conducting clinical trials, all of these hospitals also have medical research centers.